Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,762Revenue (TTM) $M416Net Margin (%)-43.2Altman Z-Score24.0
Enterprise Value $M7,256EPS (TTM) $-1.3Operating Margin %-43.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-43.2Higher ROA y-yY
Price/Book12.910-y EBITDA Growth Rate %-3.2Quick Ratio4.6Cash flow > EarningsY
Price/Sales18.55-y EBITDA Growth Rate %1.2Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-21.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-27.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M143ROIC % (ttm)-261.0Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SGEN is held by these investors:



SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2017-07-05Sell10,423$51.984.37view
DRACHMAN JONATHAN GCMO & EVP, R & D 2017-06-22Sell10,000$64.01-15.25view
SIEGALL CLAY BPresident and CEO 2017-06-05Sell10,423$65.21-16.81view
HIMES VAUGHN BChief Technical Officer 2017-05-31Sell10,000$62.59-13.32view
SIEGALL CLAY BPresident and CEO 2017-05-05Sell14,462$61.74-12.13view
SIEGALL CLAY BPresident and CEO 2017-04-05Sell14,465$62.99-13.88view
HIMES VAUGHN BChief Technical Officer 2017-03-31Sell10,000$62.75-13.55view
SIEGALL CLAY BPresident and CEO 2017-03-06Sell14,465$68.04-20.27view
SIEGALL CLAY BPresident and CEO 2017-02-06Sell14,465$61.54-11.85view
SIEGALL CLAY BPresident and CEO 2017-01-06Sell14,465$57.89-6.29view

Press Releases about SGEN :

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothel Jun 05 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Actio Mar 08 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 05 2017 
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP remi Feb 28 2017 
7 Stocks That Are Beating the Market Feb 21 2017 
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 

More From Other Websites
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda... Jul 14 2017
5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Jul 13 2017
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results... Jul 06 2017
What Analysts Recommend for United Therapeutics in June 2017 Jul 04 2017
Seattle Genetics (SGEN) Reports Positive Data for Adcetris Jun 27 2017
Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics Jun 27 2017
Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers Jun 26 2017
Why Frontier Communications, Seattle Genetics, and Arconic Slumped Today Jun 26 2017
Why Stratasys, Ltd. (SSYS), Arconic Inc (ARNC) and Seattle Genetics, Inc. (SGEN) Are 3 of Today’s... Jun 26 2017
Biotech Rally Stumbles As These Small Caps Pull Back Jun 26 2017
Seattle Genetics: A Disappointing Study…Or Was It? Jun 26 2017
Why Shares of Seattle Genetics, Inc. Got Whacked Today Jun 26 2017
Seattle Genetics slumps as cancer drug data fails to impress Jun 26 2017
J.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results Jun 26 2017
UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors Jun 26 2017
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial... Jun 26 2017
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma Jun 26 2017
Seattle Genetics Plunges After Issuing Stage 3 Trial Results Jun 26 2017
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug Jun 21 2017
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt Jun 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}